IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation

Journal of Clinical Virology

Volumn 61, Issue 2, 2014, Pages 282-285

  Fernández Carrillo, Carlos ^a,b   Coto Llerena, Mairene ^a,c   González, Patricia ^a   Crespo, Gonzalo ^a   Mensa, Laura ^a   Caro Pérez, Noelia ^a   Gambato, Martina ^a   Navasa, Miquel ^a   Forns, Xavier ^a   Pérez del Pulgar, Sofía ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Hepatitis C virus; IFNL4; Interferon treatment; Liver transplantation; Sustained virological response

Indexed keywords

INTERFERON; INTERFERON LAMBDA 4; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; DONOR; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84924035772     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.07.015     Document Type: Article

References (24)

1. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567.
2. Garcia-Retortillo M., Forns X., Feliu A., Moitinho E., Costa J., Navasa M., et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35(3):680-687.
3. Carrion J.A., Navasa M., Garcia-Retortillo M., Garcia-Pagan J.C., Crespo G., Bruguera M., et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007, 132(5):1746-1756.
4. Berenguer M., Palau A., Aguilera V., Rayon J.M., Juan F.S., Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008, 8(3):679-687.
5. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45(2):164-171.
6. Bibert S., Roger T., Calandra T., Bochud M., Cerny A., Semmo N., et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013, 210(6):1109-1116.
7. Stattermayer A.F., Strassl R., Maieron A., Rutter K., Stauber R., Strasser M., et al. Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2013, 39(1):104-111.
8. Nozawa Y., Umemura T., Katsuyama Y., Shibata S., Kimura T., Morita S., et al. Genetic polymorphism in IFNL4 and response to pegylated interferon-alpha and ribavirin in Japanese chronic hepatitis C patients. Tissue Antigens 2014, 83(January (1)):45-48.
9. Kramer B., Nischalke H.D., Boesecke C., Ingiliz P., Voigt E., Mauss S., et al. Variation in IFNL4 genotype and response to interferon-based therapy of hepatitis C in HIV-positive patients with acute and chronic hepatitis C. AIDS 2013, 27(17):2817-2819.
10. Franco S., Aparicio E., Parera M., Clotet B., Tural C., Martinez M.A. IFNL4 ss469415590 variant is a better predictor than ILF3 (IL28B) rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS 2014, 28(1):133-136.
11. Fujino H., Imamura M., Nagaoki Y., Kawakami Y., Abe H., Hayes C.N., et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol 2013, (December). [Epub ahead of print].
12. Nagaoki Y., Imamura M., Kawakami Y., Kan H., Fujino H., Fukuhara T., et al. IFNL4 polymorphism affects on outcome of telaprevir, peg-interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res 2014, (April). [Epub ahead of print].
13. Meissner E.G., Bon D., Prokunina-Olsson L., Tang W., Masur H., O'Brien T.R., et al. IFNL4-deltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis 2014, 209(11):1700-1704.
14. Coto-Llerena M., Perez-del-Pulgar S., Crespo G., Carrion J.A., Martinez S.M., Sanchez-Tapias J.M., et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011, 11(5):1051-1057.
15. Coto-Llerena M., Crespo G., Gonzalez P., Koutsoudakis G., Miquel R., Navasa M., et al. Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol 2012, 56(2):355-358.
16. Charlton M.R., Thompson A., Veldt B.J., Watt K., Tillmann H., Poterucha J.J., et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011, 53(1):317-324.
17. Lange C.M., Moradpour D., Doehring A., Lehr H.A., Mullhaupt B., Bibert S., et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2011, 55(2):322-327.
18. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139(5):1577-1585.
19. Gouw A.S., Houthoff H.J., Huitema S., Beelen J.M., Gips C.H., Poppema S. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987, 43(2):291-296.
20. Hove W.R., van Hoek B., Bajema I.M., Ringers J., van Krieken J.H., Lagaaij E.L. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transplant 2003, 9(6):552-556.
21. Kleeberger W., Rothamel T., Glockner S., Flemming P., Lehmann U., Kreipe H. High frequency of epithelial chimerism in liver transplants demonstrated by microdissection and STR-analysis. Hepatology 2002, 35(1):110-116.
22. Hamming O.J., Terczynska-Dyla E., Vieyres G., Dijkman R., Jorgensen S.E., Akhtar H., et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013, 32(23):3055-3065.
23. McGilvray I., Feld J.J., Chen L., Pattullo V., Guindi M., Fischer S., et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012, 142(5):1122-1131.
24. Amanzada A., Kopp W., Spengler U., Ramadori G., Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLOS ONE 2013, 8(12):e84026.